AriBio USA, a clinical-stage biopharmaceutical company, announced the enrollment of their first participants in their Phase 3 trial to evaluate the efficacy of AR1001 in participants with early Alzheimer's
Today AriBio Co., Ltd. announced the completion of the end of phase 2 meeting (EOP2) with the United States Food and Drug Administration (FDA), Division of Neurology 1. The EOP2 meeting, which occurred